Anifrolumab shows higher remission rates versus placebo in SLE patients regardless of immunosuppressant history
A New Lupus Drug May Work Better If You Start It Sooner
A post hoc analysis of pooled Phase 3 RCT data in 726 patients with moderate-to-severe SLE found higher DORIS remission rates with anifrolum…
Starting a new lupus drug before trying older medications may help patients reach remission faster and with fewer side effects.
Phase 3 Trial: Anifrolumab Shows Promise in SLE with BICLA Response as Primary Outcome
Could a New Treatment Offer Hope for Patients with Lupus?
In a Phase 3 trial with 367 SLE patients, subcutaneous anifrolumab was tested against placebo. The primary endpoint is the BICLA response, b…
A new subcutaneous treatment is being tested to help adults with moderate to severe lupus who aren't responding well to standard care.